Modicus Prime, a healthcare compliance software company focused on regulated artificial intelligence in life sciences, has raised $8 million in total funding following an additional $4.5 million investment led by Frist Cressey Ventures. The round also includes participation from Silverton Partners and Oncology Ventures, reinforcing investor interest in infrastructure supporting AI adoption across regulated pharmaceutical environments.
The company, formerly a resident at Johnson & Johnson Innovation – JLABS @ Texas Medical Center, said the funding will be used to expand its “Trustworthy AI Compliance Software,” a platform designed to help pharmaceutical companies deploy and manage AI systems in regulated (GxP) environments while maintaining audit readiness across global operations.
The latest capital injection brings Modicus Prime’s total funding to $8 million, as the company scales deployments across pharmaceutical manufacturers, contract research organizations (CROs), contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs), along with adjacent regulated healthcare sectors.
Modicus Prime’s platform is designed to address a growing challenge in the pharmaceutical industry: how to safely deploy AI systems while meeting strict regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The software integrates with existing pharmaceutical technology stacks and quality management systems to create a centralized compliance layer spanning the full AI lifecycle.
The system is intended to provide what the company describes as a “single source of truth” for AI governance in regulated environments, enabling organizations to align data science, IT, quality, and compliance teams around shared audit-ready frameworks. By doing so, the platform aims to reduce operational friction and ensure that AI tools used across manufacturing and clinical workflows remain compliant across geographies and regulatory frameworks.
Modicus Prime CEO Taylor Chartier, a former engineer and data scientist at Shire and Bayer Pharmaceuticals, said pharmaceutical companies are increasing investment in AI but often lack the infrastructure required to deploy these systems in a compliant and measurable way. She noted that similar needs are emerging across adjacent healthcare sectors, including payers and providers, where regulatory oversight and data governance requirements are also intensifying.
Chartier has played a prominent role in shaping industry guidance on AI adoption in regulated environments. She co-authored the ISPE GAMP AI Guide and contributed to the BioPhorum AI Implementation publication in 2025. She also led the ISPE GxP AI Webinar Series, an industry-focused educational initiative aimed at supporting standardized AI implementation in pharmaceutical operations.
Investor Senator Bill Frist, MD, founding partner of Frist Cressey Ventures, said the ability to streamline AI compliance is critical to ensuring that innovation in healthcare translates into improved patient outcomes. He emphasized that reducing regulatory complexity around AI can help accelerate the development and delivery of life-saving therapies.
Oncology Ventures founder Ben Freeberg said the platform addresses a key bottleneck in drug development and manufacturing, where AI-driven innovation must still pass rigorous regulatory audits before reaching patients. He described Modicus Prime as a foundational compliance layer supporting the next wave of oncology and pharmaceutical breakthroughs.
The pharmaceutical industry is increasingly investing in AI across drug discovery, clinical trials, and manufacturing optimization. However, regulatory compliance remains a significant barrier to scaling these systems, particularly in GxP-controlled environments where validation, traceability, and auditability are required.
Modicus Prime said the new funding will be used to expand customer support, enhance platform capabilities, and scale deployments with global pharmaceutical partners. The company is also focused on improving integration with enterprise systems and supporting broader adoption of AI across regulated workflows.
Frist Cressey Ventures, which led the round, is a healthcare-focused venture capital firm with approximately $846 million in assets under management and a portfolio centered on improving healthcare delivery, affordability, and system integration. Oncology Ventures is a specialized venture firm focused on cancer care innovation, backed by leading oncology institutions across the United States.
Modicus Prime’s platform is currently used to support AI compliance in biologics, cell and gene therapy, and vaccine manufacturing environments, where regulatory oversight is particularly stringent and operational complexity is high.
As pharmaceutical companies continue expanding AI adoption, Modicus Prime is positioning itself as a compliance infrastructure provider aimed at enabling scalable, audit-ready deployment of AI systems across global regulated healthcare operations.